# Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg

> **NCT06900166** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Huashan Hospital** · enrollment: 360 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** PegIFN alfa-2b
- **DRUG:** PegIFN alfa-2b and NUC

## Key facts

- **NCT ID:** NCT06900166
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2029-04-01
- **Final completion:** 2029-04
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06900166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06900166, "Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06900166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*